Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation

International Journal of Clinical Pharmacy

Volumn 37, Issue 6, 2015, Pages 1111-1120

  Lowres, Nicole ^a,b,c   Krass, Ines ^d   Neubeck, Lis ^d,e   Redfern, Julie ^c,e   McLachlan, Andrew J ^a,d   Bennett, Alexandra A ^a,d,f   Freedman, S Ben ^a,b,c  

^a ANZAC Research Institute   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^f NSW Therapeutic Advisory Group   (Australia)

Author keywords

Atrial fibrillation; Australia; Barriers; Enablers; Implementation; Pharmacist; Screening

Indexed keywords

AGED; ARTICLE; ATRIAL FIBRILLATION; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAM; FEASIBILITY STUDY; FEMALE; HEALTH SERVICE; HUMAN; JOB SATISFACTION; MALE; MASS SCREENING; MOBILE PHONE; PHARMACIST; PHARMACY; PRIORITY JOURNAL; PROGRAM SUSTAINABILITY; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SEMI STRUCTURED INTERVIEW; AUSTRALIA; COST BENEFIT ANALYSIS; DEVICES; ELECTROCARDIOGRAPHY; HEALTH PERSONNEL ATTITUDE; HUMAN RELATION; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; PSYCHOLOGY; QUALITATIVE RESEARCH; SMARTPHONE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; JOB SATISFACTION; MALE; MASS SCREENING; PHARMACISTS; PROFESSIONAL ROLE; PROFESSIONAL-PATIENT RELATIONS; QUALITATIVE RESEARCH; SMARTPHONE;

EID: 84945463735     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-015-0169-1     Document Type: Article

References (43)

1. Leyden JM, Kleinig TJ, Newbury J, Castle SF, Cranefield J, Anderson CS, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke. 2013;44(5):1226–31.
2. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103–8.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
4. Camm AJ, Lip GYH, Caterina RD, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
5. Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA, et al. RCPE UK consensus conference on ‘approaching the comprehensive management of atrial fibrillation: evolution or revolution?’. J R Coll Phys Edinb. 2012;42(Suppl 18):3–4.
6. Flint AC, Banki NM, Ren X, Rao VA, Go AS. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the stroke and monitoring for PAF in real time (SMART) registry. Stroke. 2012;43(10):2788–90.
7. Surka S, Edirippulige S, Steyn K, Gaziano T, Puoane T, Levitt N. Evaluating the use of mobile phone technology to enhance cardiovascular disease screening by community health workers. Int J Med Inform. 2014;83(9):648–54.
8. Hunt BD, Hiles SL, Chauhan A, Ighofose C, Bharakhada N, Jain A, et al. Evaluation of the Healthy LifeCheck programme: a vascular risk assessment service for community pharmacies in Leicester city, UK. J Public Health. 2013;35(3):440–6.
9. Armour CL, Lemay K, Saini B, Reddel HK, Bosnic-Anticevich SZ, Smith LD, et al. Using the community pharmacy to identify patients at risk of poor asthma control and factors which contribute to this poor control. J Asthma. 2011;48(9):914–22.
10. Saini B, Krass I, Armour C. Development, implementation, and evaluation of a community pharmacy-based asthma care model. Ann Pharmacother. 2004;38(11):1954–60.
11. McLean W, Gillis J, Waller R. The BC community pharmacy asthma study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J. 2003;10(4):195–202.
12. Horgan JMP, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (‘Heart MOT’ service) in community pharmacies. J Public Health. 2010;32(1):110–6.
13. Krass I, Hourihan F, Chen T. Health promotion and screening for cardiovascular risk factors in NSW: a community pharmacy model. Health Promot J Austr. 2003;14(2):101–7.
14. Peterson GM, Fitzmaurice KD, Kruup H, Jackson SL, Rasiah RL. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci. 2010;32(3):373–80.
15. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53.
16. Martin-Calero MJ, Machuca M, Murillo MD, Cansino J, Gastelurrutia MA, Faus MJ. Structural process and implementation programs of pharmaceutical care in different countries. Curr Pharm Des. 2004;10(31):3969–85.
17. Roberts AS, Benrimoj SI, Chen TF, Williams KA, Hopp TR, Aslani P. Understanding practice change in community pharmacy: a qualitative study in Australia. Res Social Adm Pharm. 2005;1(4):546–64.
18. The Australian Government, Department of Health. The fifth community pharmacy agreement between the Commonwealth of Australia and the Pharmacy Guild of Australia, 2010. http://www.healthgovau/internet/main/publishingnsf/Content/fifth-community-pharmacy-agreement (2010). Accessed 21 Sept 2014.
19. Smith JD, White C, Roufeil L, Veitch C, Pont L, Patel BF, et al. A national study into the rural and remote pharmacist workforce. Rural Remote Health. 2013;13(2):2214.
20. Mak VS, March GJ, Clark A, Gilbert AL. Why do Australian registered pharmacists leave the profession? A qualitative study. Int J Clin Pharm. 2013;35(1):129–37.
21. Eden M, Schafheutle EI, Hassell K. Workload pressure among recently qualified pharmacists: an exploratory study of intentions to leave the profession. Int J Pharm Pract. 2009;17(3):181–7.
22. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167–76.
23. Lowres N, Freedman SB, Redfern J, McLachlan A, Krass I, Bennett A et al. Screening education and recognition in community pHarmacies of atrial fibrillation to prevent stroke in an ambulant population aged ≥65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open. 2012; 2(3).
24. Charmaz K. Constructing grounded theory: a practical guide through qualitatitive analysis. Thousand Oaks, CA: Sage; 2006.
25. Australian Government Department of Health. Medication use review (MedsCheck) and diabetes medication management services (Diabetes MedsCheck), July 2014. http://www.health.gov.au/internet/main/publishing.nsf/Content/fifth-community-pharmacy-agreement-mur (2014). Accessed 27 Oct 2014.
26. Eades C, Ferguson J, O’Carroll R. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11(1):582.
27. Mansoor SM, Aslani P, Krass I. Pharmacists’ attitudes and perceived barriers to provision of adherence support in Australia. Int J Clin Pharm. 2014;36(1):136–44.
28. Emmerton L, Smith L, LeMay K, Krass I, Saini B, Bosnic-Anticevich S, et al. Experiences of community pharmacists involved in the delivery of a specialist asthma service in Australia. BMC Health Serv Res. 2012;12(1):164.
29. Law MG, Komura S, Murchison AP, Pizzi LT. Pharmacy staff opinions regarding diabetic retinopathy screenings in the community setting: findings from a brief survey. Am Health Drug Benefits. 2013;6(9):548–52.
30. Shaheed CA, Maher CG, Williams KA, McLachlan AJ. Participation of pharmacists in clinical trial recruitment for low back pain. Int J Clin Pharm. 2014;36(5):986–94.
31. Feletto E, Wilson LK, Roberts AS, Benrimoj SI. Building capacity to implement cognitive pharmaceutical services: quantifying the needs of community pharmacies. Res Soc Adm Pharm. 2010;6(3):163–73.
32. Peterson GM, Jackson SL, Hughes JD, Fitzmaurice KD, Murphy LE. Public perceptions of the role of Australian pharmacists in cardiovascular disease. J Clin Pharm Ther. 2010;35(6):671–7.
33. McMillan SS, Sav A, Kelly F, King MA, Whitty JA, Wheeler AJ. How to attract them and keep them: the pharmacy attributes that matter to Australian residents with chronic conditions. Int J Pharm Pract. 2014;22(4):238–45.
34. Hopp TR, Sørensen EW, Herborg H, Roberts AS. Implementation of cognitive pharmaceutical services (CPS) in professionally active pharmacies. Int J Pharm Pract. 2005;13(1):21–31.
35. Nelson ARJ, Zelnio RN, Beno CE. Clinical pharmaceutical services in retail practice. II. Factors influencing the provision of services. Drug Intell Clin Pharm. 1984;18(12):992–6.
36. Teeter BS, Braxton-Lloyd K, Armenakis AA, Fox BI, Westrick SC. Adoption of a biometric screening service in community pharmacies: a qualitative study. J Am Pharm Assoc. 2014;54(3):258–66.
37. Williams RB, Boles M, Johnson RE. A patient-initiated system for preventive health care. A randomized trial in community-based primary care practices. Arch Fam Med. 1998;7(4):338–45.
38. Heart Foundation Focus Grant: “Absolute risk screening in Pharmacy”. Dr Kevin McNamara, Flinders University. http://www.heartfoundation.org.au/research/current-research/Pages/McNamara_100364.aspx (2014). Accessed 17 Oct 2014.
39. The Pharmacy Guild of Australia. ‘Discover More. Ask Your Pharmacist’ campaign, 2014. http://www.guild.org.au/news-events/consumer-campaign (2014). Accessed 19 Oct 2014.
40. McGrath SH, Snyder ME, Duenas GG, Pringle JL, Smith RB, McGivney MS. Physician perceptions of pharmacist-provided medication therapy management: qualitative analysis. J Am Pharm Assoc. 2010;50(1):67–71.
41. Tannenbaum C, Tsuyuki RT. The expanding scope of pharmacists’ practice: implications for physicians. CMAJ. 2013;185(14):1228–32.
42. Hatah E, Braund R, Duffull S, Tordoff J. General practitioners perceptions’ of pharmacists’ new services in New Zealand. Int J Clin Pharm. 2012;34(2):364–73.
43. Pharmaceutical Society of Australia. PSA position statement on pharmacist involvement in preventative health care services, June 2009. http://www.psa.org.au/download/policies/involvement-in-preventitive-care-services.pdf (2009). Accessed 19 Oct 2014.